Allogenic Hematopoietic Cell Transplantation (HCT) for Chronic Myelomonocytic Leukemia: Clinical, Cytogenetic, and Mutational Risk Factors Associated with Survival

MLA

Janghee Woo, et al. “Allogenic Hematopoietic Cell Transplantation (HCT) for Chronic Myelomonocytic Leukemia: Clinical, Cytogenetic, and Mutational Risk Factors Associated with Survival.” Biology of Blood and Marrow Transplantation, vol. 25, Mar. 2019, pp. S103–04. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........0b18459bef860761f1e832186b58bafd&authtype=sso&custid=ns315887.

APA

Janghee Woo, Dae Ro Choi, Bart L. Scott, Cecilia Yeung, Barry E. Storer, H. Joachim Deeg, & Gary Schoch. (2019). Allogenic Hematopoietic Cell Transplantation (HCT) for Chronic Myelomonocytic Leukemia: Clinical, Cytogenetic, and Mutational Risk Factors Associated with Survival. Biology of Blood and Marrow Transplantation, 25, S103–S104.

Chicago

Janghee Woo, Dae Ro Choi, Bart L. Scott, Cecilia Yeung, Barry E. Storer, H. Joachim Deeg, and Gary Schoch. 2019. “Allogenic Hematopoietic Cell Transplantation (HCT) for Chronic Myelomonocytic Leukemia: Clinical, Cytogenetic, and Mutational Risk Factors Associated with Survival.” Biology of Blood and Marrow Transplantation 25 (March): S103–4. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........0b18459bef860761f1e832186b58bafd&authtype=sso&custid=ns315887.